Research
Hormonal
Prescription omega-3s (4 g/d EPA-only) reduce major adverse cardiovascular events by 25% in high-risk patients with hypertriglyceridemia who are already taking statins.
If you are at high risk for heart disease and have high triglycerides, ask your doctor about adding prescription EPA-only omega-3s (like Vascepa) to your statin. The REDUCE-IT trial showed this combination reduced major heart events by 25% compared to placebo.
StrongSupportsVERY_HIGH confidence
The use of n-3 FA (4 g/d) for improving atherosclerotic cardiovascular disease risk in patients with hypertriglyceridemia is supported by a 25% reduction in major adverse cardiovascular events in REDUCE-IT (Reduction of Cardiovascular Events With EPA Intervention Trial), a randomized placebo-controlled trial of EPA-only in high-risk patients treated with a statin.
Why this rating
Based on a large, randomized, placebo-controlled trial (REDUCE-IT).
Source
Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association
Ann C. Skulas‐Ray et al. · Circulation · 2019
DOI 10.1161/cir.0000000000000709
clinical_guidelineCited 465×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Prescription omega-3 fatty acids (EPA+DHA or EPA-only) at a dose of 4 g/d reduce triglycerides by 30-35% in patients with very high triglycerides (≥500 mg/dL) and by approximately 27% in those with high triglycerides (200-499 mg/dL).Good
- EPA-only prescription omega-3s (Icosapent Ethyl) do not raise LDL cholesterol in patients with very high triglycerides, whereas EPA+DHA combinations may increase LDL-C by 15-36%.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →